|

Iparomlimab and Tuvonralimab Clinical Trials

6 actively recruiting trials

Also known as: QL1706

Pipeline

Phase 2: 6

Top Sponsors

  • Sun Yat-sen University2
  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University1
  • Shandong Cancer Hospital and Institute1
  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University1
  • Dai, Guanghai1

Indications

  • Cancer6
  • Neoplasm Recurrence, Local1
  • First-line Treatment Failure Nasopharyngeal Carcinoma1
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma1
  • Oligometastatic1

Other6 trials

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
Phase 2
Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer
Phase 2
Iparomlimab and Tuvonralimab in HNSCC
Phase 2
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Phase 2
Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
Phase 2
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.